Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 20

1465P - Clinical impact of proton pump inhibitor on the therapeutic outcome of non-small cell lung cancer patients with PD-L1 TPS ≥50% receiving pembrolizumab monotherapy versus immune checkpoint inhibitor plus chemotherapy: A retrospective multicenter cohort study

Date

21 Oct 2023

Session

Poster session 20

Topics

Immunotherapy

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Hayato Kawachi

Citation

Annals of Oncology (2023) 34 (suppl_2): S755-S851. 10.1016/S0923-7534(23)01943-9

Authors

H. Kawachi1, T. Yamada1, M. Tamiya2, Y. Negi3, Y. Goto4, A. Nakao5, S. Shiotsu6, K. Tanimura7, T. Takeda7, A. Okada8, T. Harada9, K. Date10, Y. Chihara11, I. Hasegawa12, N. Tamiya13, M. Iwasaku1, S. Tokuda1, T. Kijima3, K. Takayama1

Author affiliations

  • 1 Pulmonary Medicine, Graduate School Of Medical Science, Kyoto Prefectural University of Medicine, 602-8566 - Kyoto/JP
  • 2 Thoracic Oncology, Osaka International Cancer Institute, 541-8567 - Osaka/JP
  • 3 Respiratory Medicine And Hematology, Hyogo Medical University, 663-8501 - Nishinomiya/JP
  • 4 Respiratory Medicine, Fujita Health University, 470-1192 - Toyoake/JP
  • 5 Respiratory Medicine, Fukuoka University Hospital, 814-0180 - Fukuoka/JP
  • 6 Respiratory Medicine, Japanese Red Cross Kyoto Daiichi Hospitall, 605-0981 - Kyoto/JP
  • 7 Respiratory Medicine, Japanese Red Cross Kyoto Daini Hospital, 602-8026 - Kyoto/JP
  • 8 Respiratory Medicine, Saiseikai Suita Hospital, 564-0013 - Suita/JP
  • 9 Medical Oncology, Fukuchiyama City Hospital, 620-8505 - Fukuchiyama/JP
  • 10 Pulmonary Medicine, Kyoto Chubu Medical Center, Nantan/JP
  • 11 Respiratory Medicine, Uji-Tokushukai Medical Center, Uji/JP
  • 12 Respiratory Medicine, Saiseikai Shigaken Hospital, Ritto/JP
  • 13 Respiratory Medicine, Rakuwakai Otowa Hospital, 607-8062 - Kyoto/JP

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1465P

Background

Pembrolizumab monotherapy and immune checkpoint inhibitor plus chemotherapy (ICI/Chemo) have been approved as first-line treatment for non-small cell lung cancer (NSCLC) with programmed death ligand 1 tumor proportion score (PD-L1 TPS) ≥50%. However, the clear distinction between the two therapeutic options remains unclear. It was reported that using proton pump inhibitors (PPI) and antibiotics correlated with poorer treatment outcomes of ICI monotherapy for NSCLC.

Methods

We retrospectively enrolled consecutive PD-L1 TPS ≥50% advanced NSCLC patients who received pembrolizumab monotherapy or ICI/Chemo as first-line treatment. We analyzed the association between treatment outcome and patient characteristics, including concomitant drug history in each group. Comparing the treatment outcome, propensity score matching was used to reduce bias.

Results

The study included 425 patients, with 271 receiving pembrolizumab monotherapy and 154 receiving ICI/Chemo. According to the multivariate analysis, a history of PPI usage was independently associated with shorter progression-free survival (PFS) in pembrolizumab monotherapy group(hazard ratio (HR): 1.38, 95.0% CI: 1.00–1.91; P = 0.048), but not in ICI/Chemo group (HR: 0.83, 95.0% CI: 0.48–1.45; P = 0.515). In patients with a history of PPI, both the median PFS (19.3 months vs. 5.7 months, P=0.002) and the median overall survival (OS) (not reached vs. 18.4 months, P=0.025) were significantly longer in ICI/Chemo group than in pembrolizumab monotherapy group. In patients without a history of PPI, the median PFS (18.8 months vs. 10.6 months, P=0.259) and the median OS (not reached vs. 29.9 months, P=0.211) was not significantly different between each group.

Conclusions

History of PPI usage was negatively associated with treatment outcome of pembrolizumab monotherapy, but not ICI/Chemo in NSCLC patients with PD-L1 expression ≥50%. Our observations in real-world settings suggest that the history of PPI usage may be a predictive clinical factor to be considered in treatment decision-making in this population.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.